Breaking WORLD PHARMA NEWS

ISTH: new data highlight innovation from Sanofi's pipeline in rare diseases

New data from 18 abstracts, including five oral presentations, will be presented at the 33rd congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington D.C., US from June 21 to 25, 2025, highlighting Sanofi as a leader in hemophilia committed to rare blood diseases. Data to be presented expand on the potential of rilzabrutinib to address the underlying immune dysregulation of immune thrombocytopenia (ITP) and strengthen Sanofi as a leader in hemophilia with ALTUVIIIO and the newly launched Qfitlia, aimed at providing more treatment options to help improve patients' lives.

Read more …

Fighting myeloma with fiber: Plant-based diet offers promise

Results from a new clinical trial suggest that a high-fiber plant-based diet could benefit patients at risk for developing multiple myeloma, the second most common type of blood cancer. The study showed that the diet was not only feasible and well-received but also improved several factors that could potentially delay the progression of precancerous conditions that can lead to multiple myeloma.

Read more …

Collaborations result in antibiotic resistance breakthrough

University of Otago - Ōtākou Whakaihu Waka researchers have been part of two groundbreaking studies in the battle against drug resistant strains of Mycobacterium tuberculosis, the cause of tuberculosis.

Co-author on both studies, Dr Matthew McNeil, of the Department of Microbiology and Immunology, describes tuberculosis as a "massive public health problem" that is challenging to solve.

Read more …

Tea, berries, dark chocolate and apples could lead to a longer life span

New research has found that those who consume a diverse range of foods rich in flavonoids, such as tea, berries, dark chocolate, and apples, could lower their risk of developing serious health conditions and have the potential to live longer.

The study was led by a team of researchers from Queen's University Belfast, Edith Cowan University Perth (ECU), and the Medical University of Vienna.

Read more …

Application of machine learning in drug side effect prediction: databases, methods and challenges

Understanding and preventing drug side effects holds a profound influence on drug development and utilization, profoundly impacting patients' physical and mental well-being. Traditional artificial drug experimentation methods are not only expensive but also time-consuming, rendering comprehensive testing a challenging task.

Read more …

DeepSeek-R1 offers promising potential to accelerate healthcare transformation

A joint research team from The Hong Kong University of Science and Technology and The Hong Kong University of Science and Technology (Guangzhou) has published a perspective article in MedComm - Future Medicine. The article comprehensively evaluates DeepSeek-R1, a Chinese-developed open-source large language model (LLM), and its potential to transform the healthcare landscape.

Read more …

Sevabertinib (BAY 2927088) granted FDA Priority Review for the treatment of patients with HER2-mutant non-small cell lung cancer

Bayer announced that the investigational compound sevabertinib (BAY 2927088) has been granted Priority Review status by the US Food and Drug Administration (FDA) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 (HER2/ERBB2) mutations and who have received a prior systemic therapy.[1] Sevabertinib is an oral, small molecule, tyrosine kinase inhibitor (TKI).

Read more …

Researchers identify drug candidate for difficult-to-treat heart disease

A study led by a physician-scientist at the University of Arizona College of Medicine - Tucson's Sarver Heart Center identified a drug candidate that appears to reverse the progression of a type of heart failure in mouse models, which could lead to expanded treatment options for humans. The results were published in the journal Cell Metabolism.

Read more …

Potential new treatment for Alzheimer's disease, other neurodegenerative conditions

Worldwide, more than 55 million people suffer from dementia caused by Alzheimer's Disease (AD) and other conditions that destroy cells in the brain and nervous system.

While there is no treatment to control or manage these neurodegenerative conditions, investigators at Case Western Reserve University, University Hospitals and the Louis Stokes Cleveland VA Medical Center have identified a new and promising drug to treat AD.

Read more …

Common antidepressants could help the immune system fight cancer

A widely used antidepressant drug could help the immune system fight cancer, according to a new UCLA research study.

Selective serotonin reuptake inhibitors, or SSRIs, significantly enhanced the ability of T cells to fight cancer and suppressed tumor growth across a range of cancer types in both mouse and human tumor models, the study, published in Cell, found.

Read more …